Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cyclerion Therapeutics,Inc. (CYCN)
NASDAQ:CYCN
Cyclerion Therapeutics (CYCN) Stock Price & Analysis
151 Followers
CYCN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.75 - $6.98
Previous Close$3.22
Volume175.00
Average Volume (3M)3.02K
Market Cap
$8.72M
Enterprise Value$1.15M
Total Cash (Recent Filing)$7.57M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)-0.4
Beta1.53
Next Earnings
May 01, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-9.07
Shares Outstanding2,710,096
10 Day Avg. Volume5,110
30 Day Avg. Volume3,018
Standard Deviation0.32
R-Squared0.09
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)0.76
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.09
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Cyclerion Therapeutics News
PremiumPress Releases
Cyclerion Announces Reverse Stock Split
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CYCN FAQ
What was Cyclerion Therapeutics,Inc.’s price range in the past 12 months?
Cyclerion Therapeutics,Inc. lowest stock price was $1.75 and its highest was $6.98 in the past 12 months.
What is Cyclerion Therapeutics,Inc.’s market cap?
Currently, no data Available
When is Cyclerion Therapeutics,Inc.’s upcoming earnings report date?
Cyclerion Therapeutics,Inc.’s upcoming earnings report date is May 01, 2024 which is in 11 days.
How were Cyclerion Therapeutics,Inc.’s earnings last quarter?
Cyclerion Therapeutics,Inc. released its earnings results on Feb 22, 2024. The company reported -$0.685 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.685.
Is Cyclerion Therapeutics,Inc. overvalued?
According to Wall Street analysts Cyclerion Therapeutics,Inc.’s price is currently Overvalued.
Does Cyclerion Therapeutics,Inc. pay dividends?
Cyclerion Therapeutics,Inc. does not currently pay dividends.
What is Cyclerion Therapeutics,Inc.’s EPS estimate?
Cyclerion Therapeutics,Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cyclerion Therapeutics,Inc. have?
Cyclerion Therapeutics,Inc. has 2,710,096 shares outstanding.
What happened to Cyclerion Therapeutics,Inc.’s price movement after its last earnings report?
Cyclerion Therapeutics,Inc. reported an EPS of -$0.685 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 10.526%.
Which hedge fund is a major shareholder of Cyclerion Therapeutics,Inc.?
Among the largest hedge funds holding Cyclerion Therapeutics,Inc.’s share is Slate Path Capital LP. It holds Cyclerion Therapeutics,Inc.’s shares valued at 1M.
---
Cyclerion Therapeutics Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.19%
12-Months-Change
Fundamentals
Return on Equity
-172.37%
Trailing 12-Months
Asset Growth
-26.02%
Trailing 12-Months
Company Description
Cyclerion Therapeutics,Inc.
Cyclerion Therapeutics, Inc. engages in the discovery, development, and commercialization of treatments for serious and orphan diseases, through the use of soluble guanylate cyclase (sGC) pharmacology. Its product pipeline includes several sGC stimulators. The company was founded on September 6, 2018 and is headquartered in Cambridge, MA.
---
Technical Analysis
Corbus Pharmaceuticals
―
Kala Pharmaceuticals
―
Cassava Sciences
―
Crispr Therapeutics AG
―
---